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ABSTRACT 
INTRODUCTION: Chronic kidney disease-mineral and bone disorders (CKD-MBD), involving a 
triad of laboratory and bone abnormalities, and tissue calcifications, are very common and are 
associated with costly complications and dismal hard-outcomes.  
AREAS COVERED: In two comprehensive articles, we review the most significant studies on 
contemporary and future pharmacological options for treatment of phosphate (P) imbalance 
(this part 1) and hyperparathyroidism (part 2), taking into account CKD-accelerated 
atheromatosis/atherosclerosis and/or cardiovascular calcification (CVC) processes.  
EXPERT OPINION: Improvements in CKD-MBD require an integral approach, addressing all 
three components of the CKD-MBD triad. Individualization of treatment with P-binders and 
combinations of anti-parathyroid agents may provide the best biochemical control with the 
lowest incidence of undesirable effects. Isolated biochemical parameters do not accurately 
reflect calcium or P load or bone activity and do not stratify high cardiovascular risk patients 
with CKD. Initial guidance is provided on reasonable therapeutic strategies which consider the 
presence of CVC. This part reflects that although there is not a clear and absolute evidence, 
many studies point to the need to improve P imbalance while trying to, at least, avoid 
progression of CVC by restriction of Ca-based P-binders if economically feasible. The 
availability of new drugs (i.e. inhibitors of intestinal transporters), and studies including early 
CKD should ultimately lead to clearer and more cost/effective clinical targets for CKD-MBD. 
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 1) INTRODUCTION    
Accelerated atherosclerosis/atheromatosis and premature ageing are closely 
associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD)1–4.  
Consequently, CKD and ESRD are linked to an extremely important increase in mortality risk as 
compared with that in the equivalent general population3,4. This disproportionate mortality 
hazard, mainly of cardiovascular origin, appears to be due to both classical and non-classical 
cardiovascular risk factors, including mineral and bone disorders (MBD)5,6. In observational 
studies, various laboratory parameters such as serum calcium (Ca), phosphate (P), magnesium 
(Mg), alkaline phosphatase (AP), calcidiol, calcitriol, fibroblast growth factor-23 
(FGF23)/klotho, and parathyroid hormone (PTH) levels have repeatedly been associated not 
only with bone disease and renal osteodystrophy but also with cardiovascular calcification 
(CVC), arterial dysfunction and, most importantly, increased morbidity and mortality, including 
sudden death6–10. In 2005 the term CKD-MBD was coined to define a triad of laboratory and 
bone abnormalities and tissue (including vascular and cardiac valvular) calcifications, all of 
which are linked to poor hard-outcomes5,11,12. Nevertheless, there is ongoing controversy 
regarding the clinical relevance of CVC screening in CKD patients 13,14, the most desirable 
biochemical targets and how to achieve them in order to improve hard-outcomes at a 
reasonable cost5,9,12,15–19. 
Mainly during the last decade, the increasing availability of new CKD-MBD-related 
treatments such as novel P-binders, vitamin D (VD) receptor activators (VDRA) and modulators 
of the Ca-sensing receptor (CaSR) –calcimimetics- has significantly increased our therapeutic 
possibilities20–22. Based on the classical “trade-off hypothesis”23, now revitalized with the 
advent of the “phosphatonin” FGF237,23, secondary hyperparathyroidism (SHPT) was 
traditionally treated with P-restricted diets, different Ca-dialysate contents, Ca-based intestinal 
P-binders, VD derivatives, and P removal by intensified dialysis therapy 5,22,24. The appearance 
of sevelamer and recognition of the FGF23/klotho axis helped to lead to a review of paradigms 
in the pathophysiology of SHPT23–26 and to increased awareness of the presence of CVC (and 
the need to quantify it), even in non-dialysis CKD patients27,28 (Figure 1). As a result, the 
concept that a non-Ca-based P-binder could attenuate the accelerated progression of CVC in 
CKD patients as compared with Ca-based P-binders was introduced28–30. It has also been 
suggested that avoidance of a Ca overload and other sevelamer-associated pleiotropic effects 
may have a positive impact on the survival of dialysis patients, but it has not been definitely 
proven31–34. On the other hand, new VDRA and/or calcimimetics may allow a more effective 
control of SHPT and may also impact on the progression of CVC, potentially leading to 
improved survival35–39 although it has not been either definitely proven35–37,40.  
Against this background, the purpose of this article is to provide an update on the 
contemporary pharmacological control of CKD-MBD, and the most recently developed drugs 
and therapeutic trends in the field. This first part focuses on agents aimed at the control of P 
imbalance and the importance of CVC progression in CKD patients, while the second part 
covers anti-parathyroid drugs and related issues. Other drugs initially designed to control CKD-
unrelated osteoporosis (such as bisphosphonates, raloxifene, and anti-RANKL or anti-sclerostin 
antibodies) are beyond the scope of these reports and we refer the reader to other recent 
reviews41. 
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2) PHOSPHATE CONTROL 
It is obvious that P is essential for life23.  However, there is a huge number of experimental and 
epidemiological studies describing that high serum P levels and/or an excessive P load are 
toxic, with impacts ranging from subclinical atheromatosis/atherosclerosis and CKD 
progression to death6,7,16,23,42–47. Several studies have also reported that it is possible to predict 
cardiovascular outcomes or mortality on the basis of serum P levels even within the normal 
range48,49. Several direct and indirect mechanisms by which P may be associated with 
endothelial, vascular and renal damage have been described, including oxidative stress, 
inflammation and a negative cross-talk with the renin-angiotensin system45,46,50. The most 
frequent cause of hyperphosphatemia is the presence of CKD, and thereby CKD serves as a 
human model where if an atherogenic role for P exposure were finally to be demonstrated, 
drugs that reduce the P overload “could become the new statins”45.These deleterious effects 
of P have also recently been dissociated from those induced by increased FGF23 or decreased 
klotho activities (inducing resistance to FGF23)2,23,45,51,52 .  
2A) PHOSPHATE-BINDERS  
Insufficient data are currently available to strongly endorse dietary P restriction as the 
primary intervention for the management of CKD-MBD, especially in stage 5D 5,53–55; but it is 
classically considered the first therapeutic step 23. Restriction of P intake (while ensuring 
adequate protein intake) is not easy and cumbersome, and is usually insufficient in patients 
with advanced CKD and dialysis patients22,56,57. Thus, a P-binder is usually required to normalize 
serum P levels or to bring P “towards normality”, as recommended by different guidelines5. 
Additionally, dietary restriction but also some P-binders may reduce FGF23 levels23,26,52. 
Routine dietary restrictions to control serum P in patients with CKD are usually 
associated with a reduction in protein intake (a manoeuver also used to delay progression of 
CKD to ESRD), which may, however, lead to malnutrition, protein-energy wasting, and poor 
survival in case of concomitant low caloric intake58,59. Low P levels are recognized as a sign of 
poor nutritional status and associated with a higher mortality risk6,58. Consequently, the 
hazards of controlling serum P levels by unsupervised restriction of dietary protein and mainly 
caloric intake may outweigh the benefits of P control and may even lead to worse survival58. 
However, limited safety data suggest that dietary P restriction does not compromise nutrition 
in a monitored setting5,54,55. Consequently, when targeting dietary P restriction the focus 
should clearly be on extra P intake (i.e. from P additives and soft drinks) not on an excessive 
protein restriction52,55,60. A qualitative modification of the diet including a balanced ingestion of 
vegetarian compared with meat dietary protein sources (“choosing the right proteins”) and 
limitation of other foods with an elevated P/protein ratio is also recommended and well 
accepted by most patients 61,62. Supplementation with ketoanalogs constitutes a different 
nutritional strategy22,63. 
There is a large body of epidemiological evidence suggesting beneficial effects of P-
binders and lowering serum P concentrations in dialysis patients5,9,64–66, although there is as yet 
no definitive primary analysis of an interventional RCT demonstrating that any P-binder 
reduces morbidity or mortality31,32. In a prospective cohort study, Isakova et al66, comparing 
patients who began treatment with P-binders during the first 90 d after initiating hemodialysis 
(n = 3555) with those who remained untreated during  that period (n = 5055), found that early 
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treatment was associated with a 25% lower 1-year mortality rate (HR 0.75; 95% CI 0.66-0.87; p 
< 0.0001). This early treatment with P-binders was independently associated with decreased 
mortality, not only in the intention-to-treat but also in the as-treated, and matched analyses66. 
Somewhat surprisingly, these results were independent of baseline and follow-up serum P 
levels and persisted in analyses that excluded deaths during the first 90 days of hemodialysis66.  
Lower adjusted hazard-ratios have also been demonstrated after adjusting for nutritional 
indicators65. In a recently published multicenter, observational prospective study of 6797 
European dialysis patients (COSMOS study), lower serum P and Ca levels towards the defined 
“safest ranges” (P 3.6-5.2 mg/dl; Ca 7.9-9.5 mg/dl) were associated with a lower relative risk of 
mortality using penalized splines smoothing analyses9. Previously, the use of single and 
combined P- binding agents was also found to be independently associated with improved 
survival after a 3-year follow-up64. Multivariate analyses also revealed that patients prescribed 
P-binders showed a 29% and 22% reductions in all-cause and cardiovascular mortality risk, 
respectively64. An 8% lower relative-risk of death was found for every 10% increase in the case-
mix-adjusted facility prescription of P-binders64. Importantly, it was shown for the first time 
that, with the exception of aluminum salts, not only all single (Ca-based and non-Ca-based P-
binders such as sevelamer and lanthanum) but also combined therapies were associated with 
better survival64. Avoidance of long-term use of aluminum-containing P-binders had previously 
been recommended in several guidelines5.    
 
2.1.1) CLASSICAL CA-BASED vs NON-CA-BASED P-BINDERS (Sevelamer and 
Lanthanum) 
KDIGO guidelines suggest to use “P-binding agents in the treatment of 
hyperphosphatemia” in patients with CKD stages 3-5 and 5D, and that it is reasonable 
for the choice of P binder to take into account CKD stage, presence of other 
components of CKD-MBD (e.g. CVC), concomitant therapies (e.g. VDRA and/or 
calcimimetics), and side effect profile5. Moreover, in patients with CKD stages 3-5D 
(dialysis and non-dialysis patients) and hyperphosphatemia, the guidelines state, “we 
suggest restricting the dose of Ca-based P-binders in the presence of arterial 
calcification [not only severe calcification as suggested in the previous 2003 National 
Kidney Foundation (NKF)/Kidney Dialysis Outcome Quality Initiative (KDOQI™) 
guidelines], and/or adynamic bone disease (ABD), and/or if serum PTH levels are 
persistently low”5,67. The reasons underlying these statements are (a) all P-binders are 
effective in lowering serum P levels, (b) the use of sevelamer or lanthanum does not 
adversely affect bone histology in short-term studies, and (c) compared with Ca-based 
P-binders, sevelamer and lanthanum may be less likely to lead to high serum Ca, lower 
PTH levels and ABD5,68–71. Additionally, (d) non-Ca based P-binders have been shown to 
attenuate progression of CVC in several studies, including randomized clinical trials 
(RCTs) and a recent meta-analysis29,72–75. However, these results have not been 
uniform76. Most importantly, it is not clear whether slowing the progression of CVC 
translates into improvements in hard-outcomes31,32. This statement also holds true for 
calcimimetics37,38,40. 
In line with the findings of a previous secondary analysis of a large RCT in 
dialysis patients31, a survival benefit has now been described for non-Ca-based P-
binders, mainly sevelamer, in small CKD dialysis and also non-dialysis populations28,77, 
and in two recent large meta-analyses33,78. However, these results are not completely 
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consistent68. Moreover, the studies did not address whether non-Ca-based P-binders 
are inherently beneficial or whether Ca-based P-binders are harmful. As a matter of 
fact, in some studies Ca-based P-binders were titrated to high doses because of 
protocol-driven targets and extrapolation to situations of low-Ca exposure and 
combination therapy should be made with caution53. Consequently, strong universal 
recommendations cannot be made5. 
It was recently shown that 1,500-mg/day of oral Ca carbonate induced a 
positive Ca balance but did not affect the P balance in predialysis stage 3-4 CKD 
patients under metabolic ward conditions79. Questions remain as to whether these 
effects would persist over time and where (soft tissues or bone) and how the retained 
Ca load would be deposited53. In another study, it was described that normal 
individuals and patients with late stage 3 and stage 4 CKD were in slightly negative to 
neutral calcium balance on an 800-mg/day Ca diet, whereas on a 2000-mg/day diet 
normal individuals were in modest positive Ca balance and patients with CKD were in 
marked positive Ca balance, at least over the 9 days of the study80. It is not surprising, 
then, that Di Iorio et al28 reported that in patients with CKD stage 3-4, moderately 
hyperphosphatemic in average, all-cause mortality and the composite end point of all-
cause mortality and dialysis inception were lower in patients randomized to sevelamer 
as compared with those randomized to Ca carbonate over a period of 36 months. This 
study did not include a placebo-control group but, in a previous observation, total 
coronary Ca score was found to be significantly increased in patients following a low-P 
diet alone, increased to a lesser extent in Ca carbonate-treated patients, and not 
increased at all in sevelamer-treated patients77. Nonetheless, a recent placebo-
controlled RCT, in patients with CKD stage 3b-4 (mean estimated glomerular filtration 
rate 30-33 ml/min/1.73m2) and a mean serum P of 4.2 mg/dl, revealed an unexpected 
increase in CVC in CKD patients on active treatment with Ca acetate, sevelamer or 
lanthanum carbonate, although the increase was more pronounced in the Ca acetate 
subgroup81. Other studies have not shown impacts of P-binder intervention on pulse-
wave velocity or other markers of cardiovascular disease in non-dialysis CKD82. Urgent 
studies are needed to solve this conundrum13,14,16,17. 
Although the potential benefits of non-Ca-based P-binders are usually 
attributed to a lower Ca burden and the possibly associated decrease in progression of 
VC and its harmful effects, other non-P-lowering effects may also be responsible for 
improved survival. Among other beneficial pleiotropic effects, the lipid-lowering 
properties of sevelamer are well documented and further positive actions have been 
documented on inflammation, oxidative stress, endothelial dysfunction, atherogenesis, 
several uremic toxins, uric acid, glycosylated haemoglobin levels and advanced-
glycosylation end-products, bacterial lipopolysaccharides, Wnt/B-catenin pathway, and 
energy-related hormones (e.g. leptin)83. These effects of sevelamer, a P-binder 
restricted to the intestinal lumen, underline the importance of the intestinal pathway 
in CKD and are opening the way to new therapeutic strategies for the management of 
CKD and its complications83. Non-Ca-based P-binders including sevelamer, lanthanum 
and others (see below) decrease serum FGF23 levels83–85, and at least to a certain 
extent, this action may contribute to improved survival even though the FGF23 
reductions are not always sustained51,86. A better nutritional status in patients treated 
with P-binders and a more liberal diet cannot be ruled out as contributing factors58,65. 
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  2.1.2) ASSOCIATION of CA AND MG AS P-BINDERS  
Low serum Mg levels are not uncommon in CKD patients and have been 
associated with a high cardiovascular risk and mortality87–89. Observational studies of 
dialysis patients have shown that low serum Mg levels occur concurrently with mitral 
annular calcification, peripheral arterial calcification, and increased carotid intima–
media thickness. Experimental studies have shown that Mg inhibits CVC, by both direct 
and indirect effects on the vessel wall87,90. Small interventional studies suggested that 
long-term administration of oral Mg supplements to hemodialysis patients might 
retard CVC (in the absence of a control group)91, and led to a significantly lower carotid 
intima–media thickness92. Another recent pilot study randomized 72 stable 
hemodialysis patients to a regimen containing Mg carbonate and Ca acetate vs one 
containing Ca acetate alone93. It was shown that, after a 12-month follow-up period, 
patients on the Mg-containing regimen had retarded CVC93. 
In spite of these findings, a beneficial role of Mg supplementation in CKD, and 
in particular on cardiovascular morbidity and mortality, has not been clearly 
demonstrated to date. Nevertheless, Mg has also been associated with a variety of 
positive effects: it acts on the CaSR (though less potently than Ca) and has been held 
responsible for anti-arrhythmic and other pleiotropic effects87. Serum Mg levels also 
significantly modify the mortality risk associated with hyperphosphatemia in 
hemodialysis patients89. Among patients with serum P levels of ≥6.0 mg/dL, the 
cardiovascular mortality risk decreased significantly with increasing serum Mg levels89. 
Consequently, despite the absence of long-term data and appropriate RCTs on 
hard-outcomes, contemporary combinations of Mg with low doses of Ca (MagneBind®, 
Osvaren®) may be considered as cost-effective alternatives in the treatment of 
hyperphosphatemia in dialysis patients unless ABD, hypercalcemia or persistently low 
PTH levels are present21,93,94. They also decrease serum FGF23 levels95. A comparison 
among these P-binders is shown in Table 1. 
2.1.3) NEW INTESTINAL P-BINDING AGENTS: 
Dietary P restriction does not usually achieve clinical goals by itself54,96. 
Improper P labelling and lack of affordable healthy foods contribute to the problem52. 
Actually, more than one-third of CKD dialysis patients still remain hyperphosphatemic 
despite all currently available treatments5.  Therefore, optimal P control is still an 
unmet need in CKD and the long historical search for the best possible intestinal P-
binder continues20,21,56,57. Tolerance, long-term adherence (term currently preferred to 
“compliance”), and clinical effectiveness are still far from ideal, in part due to the 
excessive pill burden and the need to be taken at meal time57,97,98. Thus, compliance 
with P-binder prescription is a fact of paramount importance in attaining significant 
biochemical and  clinical goals98,99. It has been actually stated that the most effective P-
binder yet discovered is the one that the patient will take100. Actually, if serum P levels 
remain high, physicians tend to increase the prescription of P-binders, only aggravating 
the situation and further worsening drug adherence101.   
New galenic formulations, have been developed with the ultimate aim of 
improving adherence by decreasing the number of pills or by administration of 
palatable oral suspensions97,102. Sevelamer carbonate [Renvela® tablets (800 mg) or 
powder (800-2400 mg)] increases the dosage options and avoids the metabolic 
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acidosis associated with sevelamer hydrochloride (Renagel®, 800 mg)102,103. The new 
lanthanum carbonate (Fosrenol®) presented as an oral powder is miscible with soft 
food as if it were a sort of seasoning (“salt for kidney patients”)97. 
 
Beyond frequent secondary effects [mainly of gastrointestinal (GI) origin], 
attempts to find P-binders have been fraught with problems in the form of new 
diseases (aluminum-based P binders), concerns about hypercalcemia and/or 
cardiovascular toxicity (Ca-based P-binders), concerns about tissue accumulation 
(lanthanum), and excessive cost (i.e. sevelamer, lanthanum)16,17,56,57. For cultural and 
other reasons104, most recent P-binders (as well as ESRD-related drugs) have been 
initially developed in Japan.   
2.1.3.1) COLESTILAN (MCI-196)  
 
Colestilan (BindRen®) has been described as a new, non-metal, non-Ca-
based P binder. It is a non-absorbable anion-exchange resin which has long 
been used in Japan for dyslipidemia treatment. Similarly to sevelamer, 
colestilan binds P and bile acids in the GI tract, significantly decreasing serum P 
and LDL-cholesterol levels105,106. Lower uric acid and glycosylated haemoglobin 
levels have also been described105–108. Most reported adverse events have 
been of mild or moderate intensity, the most common being GI complaints 
such as nausea, vomiting and diarrhea105. Colestilan was launched in Germany 
and Austria in 2013, but it is not available anymore in the European Union 
because of commercial reasons. 
 
2.1.3.2) CHITOSAN 
  
Chitosan (RenaGum™), released in some countries as a “medical food”, 
was developed as a chewing-gum that potentially binds the P contained in the 
1 to 1.5 liters of saliva produced every day109,110. As an add-on therapy to 
standard P-binders, it seemed to contribute very significantly in reducing 
serum P levels in CKD patients109; however, despite the initial great 
expectations, recent randomized studies have been unable to duplicate those 
results110,111. 
2.1.3.3) IRON-BASED P-BINDERS 
The effects and safety of iron-based P-binders as an alternative in the 
treatment of hyperphosphatemia in dialysis patients have been analyzed in a 
recent systematic review and meta-analysis112. These P-binders have generally 
been shown to be non-inferior to sevelamer (although they lack of its 
pleiotropic effects) and to be relatively well tolerated. However, there are 
many significant differences among them, regarding P-binding chemistry, iron 
absorption profiles and number of pills21,113,114. Sucroferric oxyhydroxide and 
ferric citrate are currently available in clinical practice in several 
countries21,22,56,57,113,114. Both decrease FGF23115, adding to the interesting new 
relationships described between iron and FGF2323. Since they are Ca-free, it is 
not surprising that in rat models of uremia these P-binders prevent CVC116.  
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   Sucroferric oxyhydroxide 
Sucroferric oxyhydroxide (SFe-OOH, PA21, Velphoro®) is a new 
chewable and flavored Ca–free polynuclear iron-based P-binder117–119. The 
binding of the P-iron complex is strong; SFe-OOH is consequently poorly 
soluble and it has an excellent binding capacity per prescribed unit120. These 
properties allow a lower pill-burden and almost no absorption of the ferric 
compound as compared with ferric citrate.  
The initial daily SFe-OOH dose to control hyperphosphatemia is 3 
pills/day (2500 mg or 500 mg of iron/pill). Flöege et al recently reported SFe-
OOH to be effective in lowering serum P in dialysis patients, with similar 
efficacy to sevelamer carbonate, a lower pill burden (3.1 vs 8.1), and better 
adherence in a short-term study118. More treatment-emergent adverse events 
were described in the SFe-OOH group (45.1% vs 33.6 % with sevelamer), but 
this difference was mainly due to discolored feces (15.4% vs 0.3%) and 
diarrhea (20.1% vs 7.5%).  The serum P-lowering effect was maintained over 1-
year with a lower pill burden (4.0 vs 10.1) with no evidence of iron 
accumulation, and the GI-related adverse events decreased over time119. 
Patient adherence was 86.2% with SFe-OOH versus 76.9% with sevelamer119. 
Additionally, a decrease in baseline mean serum FGF23 levels has been 
observed after 1-year of SFe-OOH, although the reduction was significantly 
lower than with sevelamer121. Finally, it is worth mentioning that SFe-OOH, 
similarly to lanthanum, does not seem to interfere with the absorption or 
bioactivity of fat-soluble vitamins (such as A, D, E, and K), which may represent 
a difference from sevelamer and other P-binders122. There is also a low risk of 
drug-drug interactions between SFe-OOH and many commonly used drugs, 
and SFe-OOH may therefore be administered concomitantly 123. Iron salts, but 
also Ca-carbonate, sevelamer, lanthanum and aluminum, among others, 
interfere with the absorption of oral levothyroxine124. 
   Ferric citrate 
Ferric citrate (Auryxia™, previously known as Zerenex®, JTT-751 or KRX-
0502) is also non-inferior to active comparators (sevelamer carbonate and/or 
Ca acetate)125–127. In addition, the drug delivers a significant amount of iron, 
resulting in significantly increases in iron stores, and lowers intravenous (iv) 
iron requirements and long-term erythropoietin-stimulating-agent dose, 
making it suitable for patients requiring iron supplementation57,126,128. 
However, it has been reported that some patients exceed a desirable serum 
ferritin or transferrin saturation level in patients already treated with iv iron128, 
and thus iron parameters should be closely monitored. Citrate may also 
increase aluminum absorption. Diarrhea is also frequent.  
Other iron-based P-binders  
Fermagate (iron-Mg hydroxycarbonate), SBR-759 (a polymeric complex 
of iron and starch), PT-20 (ferric-hydroxide adipate) and cross-linked chitosan 
iron-(III) are currently in different phases of development57,112,114,129. Old papers 
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reported that iron-dextran, iron-hydroxide, and iron-saccharide also bind P 
effectively57. 
 
2.1.3.4) Bixalomer and others  
Other P-binders are currently in development57.  Bixalomer, an amine-
functional non-absorbable polymer recently marketed in Japan, has been 
shown to be useful in treating hyperphosphatemia, with fewer GI side effects 
(not always confirmed) as compared with sevelamer, probably due to its four 
times lower swelling index demonstrated in preclinical studies130. A 
prospective observational study and a “double-blind, randomized, placebo- 
and sevelamer hydrochloride- controlled open-label, parallel group study” 
have recently been published130,131. 
Other new non-iron-based P-binders such as Genz-644470 have been 
evaluated in humans57, whereas only preclinical data are available for the 
poly(allylamine) polymer TRK-39026,132. 
 
2.2. INTESTINAL SODIUM-P COTRANSPORTER INHIBITORS 
 
An alternative mechanism to control serum P levels is directly blocking P absorption by 
means of inhibitors of the intestinal type II sodium (Na)-dependent P co-transporter 
(NPT2b)57,133,134. It is known that P depleted diets and all intestinal P-binders may upregulate 
the intestinal NPT2b expression, leading to enhanced absorption of available intestinal P when 
dietary P loading is reinstated and even during P-binder intermittent treatment84,134,135. This 
may explain why spikes in serum P levels with dietary P loading are seen only after a period of 
dietary P depletion. Thus, P-binder action may be limited by NPT2b upregulation and resultant 
increases in dietary P absorption when P-binders are inappropriately dosed84,134, at least 
partially explaining the poor control of serum P levels in many patients. Consequently, 
inhibitors of the NPT2b may become not only an important alternative84,134, but it is also 
possible that they could boost the P-binder individual effects as adjunctive therapy52,84,136. A 
very important additional advantage is that there is no strict need to take them with meals, 
potentially leading to better patient adherence135. 
  2.2.1) NICOTINAMIDE (NIACINAMIDE)     
 Nicotinamide (also known as niacinamide) is the amide of nicotinic acid 
(vitamin B3/niacin) and acts as a direct inhibitor of P absorption by blocking the 
intestinal NPT2b57,135,137. Nicotinamide does not appear to affect Na-independent P 
transport and may promote phosphaturia by reducing the expression of the renal 
cotransporters NPT2a and NPT2c135. Thus, nicotinamide may represent an effective 
and inexpensive alternative or adjunctive therapy for hyperphosphatemia in CKD 
patients135,136,138.  
 Nicotinic acid is converted to nicotinamide in vivo and, although the two are 
identical in their vitamin functions, nicotinamide does not have the same 
pharmacological and toxic effects. Unlike nicotinic acid, the metabolite nicotinamide 
does not cause flushing and it is thought to be less likely to cause other adverse events 
related to the nicotinic acid moiety (liver test abnormalities, hyperuricemia or insulin 
resistance, etc.). Different secondary effects seem also to be present when using 
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immediate-release or extended-release forms. Concerns have been expressed 
regarding the potential accumulation of a by-product [N-methyl-2-pyridone-5-
carboxamide (2PY)] in CKD and it has been suggested that 2PY is a potential uremic 
toxin135. Diarrhea and thrombocytopenia are the most frequent adverse events. 
Although earlier findings to the contrary were reported, beneficial effects on lipid 
levels have been described for nicotinamide139. Since nicotinic acid or nicotinamide 
may reduce dietary P absorption, serum P, and FGF23 levels, a novel therapeutic 
approach to lower serum P and FGF23 levels is being tested in the COMBINE study 
(The CKD Optimal Management With BInders and NicotinamidE study)84. 
 
2.2.2) OTHER INTESTINAL P-TRANSPORTER INHIBITORS  
 Several pharmaceutical companies are currently performing preclinical studies 
analyzing the effect of potential NPT2 (NPT2b and/or NPT2a,c) inhibitors, distinct from 
vitamin B3 derivatives. ASP3325 is currently being assessed in Phase 1 studies for the 
treatment of hyperphosphatemia in dialysis patients140,141. Finally tenapanor (also 
known as AZD1722 and RDX5791), a minimally systemically available inhibitor of the 
antiporter sodium-proton exchanger NHE3, is being evaluated in clinical trials for its 
potential to lower GI Na-absorption, improve fluid overload-related symptoms such as 
hypertension and proteinuria in patients with CKD and reduce interdialytic weight gain 
and intradialytic hypotension in ESRD142. In preclinical studies, tenapanor has also been 
shown to reduce intestinal P absorption, decrease serum P and FGF23 levels, and 
significantly decrease cardiovascular calcifications and heart mass142.  
 
 2.3) INHIBITORS OF THE FGF23 RECEPTOR (FGFR) 
Toxic effects of increased FGF23 (or decreased klotho) activities have been dissociated 
from P-loading7,52. The consequences of abnormal P homeostasis are evident at estimated 
glomerular filtration rates <70 ml/min/1.73m2, long before serum P levels increase143. High 
levels of FGF23 not only may reflect P imbalance but are also directly implicated in left 
ventricular hypertrophy via a klotho-independent signaling pathway50,52. These seemingly 
distinct, but perhaps additive, adverse effects of P on the cardiovascular system may suggest 
that future interventions will need to simultaneously target P and FGF23 (and/or klotho) to 
reduce cardiovascular mortality52. Trade-offs between FGF23 and other regulators of P 
metabolism could make interpretation of P balance difficult26,57.  The issue is further 
complicated by the fact that it is possible that P-binders may favorably affect P balance with 
little discernable effect on serum P levels, especially in CKD patients not yet on dialysis82,96,144. 
The lack of a standard assay for FGF23 (and klotho) is obviously not helpful52. Moreover, 
reducing intestinal P absorption with a P-binder does not always induce sustained reductions 
in FGF23 despite lower phosphaturia, suggesting that factors other than P burden may be 
responsible for driving increases in FGF23 in CKD patients86. Similarly, it has recently been 
shown that P intake is not tightly linked with serum P concentrations in CKD stages 3-5, and 
the evidence that greater P intake, assessed by 24-h urinary P excretion, is associated with 
ESRD, cardiovascular disease, non-cardiovascular disease, or all-cause mortality in these 
patients remains incomplete54. Dietary P restriction suppresses phosphaturia but does not 
always prevent FGF23 elevation in experimental CKD145. Hence, it has again been suggested 
that factors other than dietary intake may be key determinants of serum P and FGF23 
concentrations54,145.  
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Alternative theoretical approaches to decrease the deleterious effects of elevated 
serum P and FGF23 levels could be based on either direct blocking of the actions of FGF23 
(anti-FGF23 antibodies or FGFR-blockers) or klotho delivery23,52,146. Biological agents that 
directly target FGF23 are in development147,148. Animals treated with anti-FGF23 antibodies 
improved CKD-associated hyperparathyroidism147; however, anti-FGF23 antibodies increased 
mortality associated with dose-dependent increases in serum Ca and P levels, and aortic 
calcification147. These findings suggest that complete abolition and/or direct inhibition of 
FGF23, as a counter-regulatory hormone, without targeting the distinct adverse effects of high 
serum P levels is undesirable23,52. Anti-FGF23 antibodies and FGFR-blockers could still be 
useful, either in combination with P-lowering therapy or in patients with ESRD without 
significant residual renal function52. Moreover, if distinct FGFR mediate off-target effects of 
FGF23, it might be possible to design molecules that selectively block the undesirable effects of 
FGF2323,52. 
 
3) CONCLUSION 
Improvements in CKD-MBD require an integral approach, addressing all 3 components 
of the CKD-MBD triad. In addition to laboratory and bone abnormalities, CVC are a prominent 
feature of CKD and CKD-MBD and are directly linked to dismal clinical outcomes3,5. There is an 
ongoing debate on the clinical relevance of CVC13,14, but evaluation of CVC may improve both 
individual risk prediction and personalization of treatment strategies13. Consequently, we have 
shown in this article a large body of evidence describing that serum P is strongly associated 
with CVC, morbidity and mortality, that there is a huge accumulation of data favoring control 
of P overload, and that P control is currently considered one of the key issues for management 
of CKD-MBD. 
 
4) EXPERT OPINION 
Insufficient data are currently available to strongly endorse dietary P restriction as the 
primary intervention for the management of CKD-MBD, especially in stage 5D5; but it has been 
classically considered the first therapeutic step23. Restriction of P intake (while ensuring 
adequate protein intake) is not easy and cumbersome, and is usually insufficient in patients 
with advanced CKD and dialysis patients. Thus, we enforce early use of P-binders when 
hyperphosphatemia is present and a correct (and controlled) dietary protein restriction has 
already been prescribed. 
According to guidelines, the choice of P-binder should be individualized (Table 2), but 
until more definitive studies are conducted, we favor limiting the use of Ca based P-binders as 
much as possible and depending on the available resources, especially in patients with ABD or 
low PTH levels, the elderly, diabetics, patients with CVC, and those on active VD or coumadin 
treatment. We have shown that there is reasonable evidence that progression of CVC can be 
attenuated. While acknowledging that it is as yet unproven whether such an approach helps to 
improve outcomes in affected patients, initiatives to control pro-calcifying mineral metabolism 
treatment regimens seem prudent whereas multi-interventional independent RCTs and 
prevention of arterial lesions at earlier-stages appear distant possibilities.  
Among non-Ca-based P-binders, we highlight that the widest clinical experience, the 
highest number of important clinical studies, and the most pleiotropic effects have been 
described for sevelamer (“benchmark” in most clinical studies); nevertheless, lanthanum and 
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the new sucroferric oxyhydroxide display excellent P-binding capacity per prescribed unit. 
Lower amounts of Ca are prescribed with Mg/Ca-based P-binders and use of a combination of 
several P-binders is also plausible. Targeting alternative mechanisms such as inhibition of 
intestinal or renal transporters by nicotinamide or newly developed P-transport inhibitors may 
improve the important limitations of GI P-binding; however, the safety profile of these agents 
and long-term results remain to be seen. Although no single RCT has definitely demonstrated 
an improvement in hard-outcomes as a result of any CKD-MBD-related treatment (including 
absolute or relative reductions in serum P levels), and interesting debates persist13,14,16,17, we 
favor bringing serum P levels as close to normality as reasonably possible (at least < 5.2 or 5.0 
mg/dl in dialysis patients)9,149 using sound and rational measures and taking into account 
patient experiences.  
We have shown that serum P levels may not reliably reflect P balance and that its 
consequences are already evident before serum P levels rise above the normal range. 
However, although early treatment seems to be the most desirable approach, a huge vacuum 
of knowledge still exists in the predialysis population without hyperphosphatemia and high 
FGF23 levels/phosphaturia. Consequently, primary prevention of hyperphosphatemia is still 
not widely substantiated; unfortunately, contradictory and unexpected results have been 
published in this regard16,17,28,81, particularly if coupled with Ca loading16,81. 
We finally conclude that individualization of P-binders and reasonable combinations 
with anti-parathyroid agents may currently provide the best possible biochemical control with 
the lowest incidence of undesirable effects. P imbalance should not be separated of other 
laboratory parameters such as Ca, PTH, CVC and probably other cardiovascular risk factors. As 
pressure on health resources mounts further, attention should focus not merely on absolute 
costs but also on the potential health risks of drugs which may favor CVC (such as Ca-based P-
binders or high doses of VDRA) and its costly associated pathology18,19. Cheap and readily 
accessible means of assessing CVC, including lumbar, thoracic, pelvis and hand X-rays and 
echocardiography, may be of growing relevance in this context5,27, and the recent arrival of 
generic P-binders will help to reduce the bill while waiting for potentially definitive studies to 
be done. In order to integrate all the provided information, we suggest that the reader also 
takes account of the expert opinion section expressed in the second part of this article150. A 
summary is shown on Table 2.  
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Article highlights 
• CKD is linked to an extremely important and independent increase in morbidity and 
mortality 
• Mineral and bone disorders (MBD) explain part of this disproportionate risk 
• The term CKD-MBD was coined to define a triad of laboratory and bone 
abnormalities and tissue calcifications (including vascular and cardiac valvular), all of 
which are link to poor hard-outcomes 
• Treatment of CKD-MBD requires an integral approach, addressing all 3 components 
of the CKD-MBD triad (including potential consideration of CVC by X-rays) 
• Serum P and FGF23 are strongly associated with cardiovascular morbidity and 
mortality 
• Avoidance of P overload and serum P control, ideally towards normophosphatemia, 
is one of the key issues for management of CKD-MBD 
• Management of P is achieved by careful dietary P restriction, the individualized 
prescription of P-binders, reasonable combinations with antiparathyroid-agents, 
and adequate dialysis 
• We favor limiting the use of Ca-based P-binders as much as possible and depending 
on the available resources, especially in patients with ABD or low PTH, the elderly, 
diabetics, patients with CVC, and those on active vitamin D or coumadin treatment 
• Combination of P-binders is plausible 
• Targeting alternative mechanisms such as inhibition of intestinal or renal 
transporters may improve clinical results 
• Primary prevention of hyperphosphatemia is still not widely substantiated 
• RCTs including patients with early CKD should ultimately lead to the definition of 
clearer and more cost-effective biochemical and clinical targets for CKD-MBD 
• It is not 1A-evidence level proven whether any of these approaches helps to 
improve hard-outcomes in affected patients, but these regimens seem prudent to 
avoid iatrogenic progression of CVC whereas multi-interventional independent RCTs 
and earlier stage prevention of arterial lesions appear distant possibilities. 
 
This box summarizes key points contained in the article 
 
CKD: chronic kidney disease; MBD: mineral and bone disorders; CKD-MBD: chronic kidney 
disease-mineral and bone disorder; CVC: cardiovascular calcification; P: phosphate; FGF23: 
fibroblast growth factor 23; Ca: calcium; PTH: parathyroid hormone; RCT: randomized clinical 
trial 
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Table 1: Comparison among classical phosphate binders 
 
ADVANTAGES DISADVANTAGES 
SEVELAMER 
- Sevelamer 
hydrochloride 
(Renagel®) 
 
 
- Sevelamer 
carbonate  
(Renvela®) 
• Toxicity free 
• ↓ LDL cholesterol 
• Other pleiotropic effects 
(see text) 
• Powder presentation 
• ↓ FGF-23 
• Attenuation of the 
progression of VC 
(RCTs) 
• Nominally significant 
survival benefits 
(secondary predefined 
analysis of RCT, meta-
analysis) 
• High pill burden 
• GI side effects 
• Potential 
interferences with 
vitamin D and 
vitamin K GI 
absorption 
• Normal anion gap 
metabolic acidosis 
with sevelamer 
hydrochloride 
• Cost and availability 
LANTHANUM 
CARBONATE 
(Fosrenol®) 
• Aluminum and calcium 
free 
• Reduced pill burden 
• Higher P-binding 
capacity 
• Powder presentation 
miscible with food 
• Radioopacity 
(adherence?) 
• ↓ FGF-23 
• Attenuation of the 
progression of VC 
• GI side effects 
• Potential for tissue 
accumulation* 
• Difficulties in 
chewing tablets 
(potential need for a 
crusher)  
• Radioopacity 
(interference with 
VC) 
• Cost and 
availability 
CALCIUM-
MAGNESIUM  
(Osvaren®, 
MagneBind®) 
• Cost-effective 
• Decreased Ca load as 
compared to Ca-based P-
binders  
• Pleiotropic effects (see 
text) 
• ↓ FGF-23 
• Attenuation of the 
progression of VC 
• GI side effects 
• Potential for 
hypercalcemia and 
hypermagnesemia 
• Shorter clinical 
experience 
• Availability 
 
GI: gastrointestinal; P: phosphate; LDL: low-density lipoprotein; FGF-23: fibroblast 
growth factor-23; RCT: randomized clinical trial; VC: vascular calcification 
*Only experimental, and not demonstrated in regular clinical use  
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Table 2. Summary of the treatment of secondary hyperparathyroidism and CKD-MBD 
 
 
Use knowledge of VC to guide treatment of CKD-MBD, use drugs in combination, and 
individualize treatment. 
 
Phosphate (and/or FGF23) control: (P-binders) 
Achieve P levels as close to normality as possible with reasonable measures, including 
optimization of dialysis* 
Avoid additives by all possible means. 
Prioritize a balanced vegetarian vs animal dietary protein source 
Limit↑ P/protein index foods. 
Prioritize P-binder prescription over unsupervised non-specific protein diet restriction. 
If very high serum PTH and P levels are present, consider the possibility that P may NOT be 
of intestinal origin. 
Personalize choice of P-binder prescription depending on: 
• 1- Patient preferences 
• 2- CKD stage (dialysis vs non-dialysis) 
• 3- Presence/absence/degree of VC  
Avoid Ca-based P-binders in patients with hypercalcemia, low PTH levels, and/or 
ABD. Avoid or limit Ca-based P-binders in diabetics, patients with VC, and patients 
treated with coumadin. 
• 4- Concomitant therapies (i.e., VDRA, calcimimetics) 
• 5- Side effect profile (i.e., palatability, constipation, diarrhea)  
Combination of P-binders is possible. 
New P-binders may improve adherence by allowing a lower number of pills. 
Inhibition of intestinal transporters may soon become an alternative or add-on therapy to 
improve clinical effectiveness. 
 
PTH control (specific anti-parathyroid treatment) (see Part II)232  
Aim for iPTH levels between 2 and 5 times the upper limit of normality and avoid extremes 
of risk (<2X or >9X).  
Treat tendencies and do not respond to minor variations in PTH. 
Initial drug selection may be based on CKD stage, Ca and P levels as well as on other 
aspects of CKD-MBD (e.g., VC). 
Cinacalcet is not approved for the treatment of secondary hyperparathyroidism in CKD 
stages 3-5 
In CKD stage 5D, use vitamin D and calcimimetics in combination to improve efficacy with 
fewer secondary effects, eventually always considering the Ca and P levels 
Selective VDRA (paricalcitol) may provide a wider therapeutic window, especially in those 
with a trend toward hypercalcemia or hyperphosphatemia, diabetic patients, and those prone 
to VC (experimental). 
Cinacalcet is considered first-line treatment in hypercalcemic dialysis patients.  
I.V. etelcalcetide may improve compliance. 
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CKD-MBD: chronic kidney disease-mineral and bone disorder; P: phosphate; Ca: 
calcium; VC: vascular calcification; ABD: adynamic bone disease; VDRA: vitamin D 
receptor activators; iPTH: intact parathyroid hormone; i.v.: intravenous; <2X->9X: less 
than 2 times or more than 9 times the upper limit of normality for the assay.  
*Curiously, just in the summary of product characteristics of non-Ca based P binders it 
is stated that they are indicated for the control of hyperphosphatemia in adult patients 
with CKD not on dialysis only with serum P > 1.78 mmol/l (5.5 mg/dl). 
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FIGURE 1. 
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Legend Figure 1. Changes in therapeutic strategies for secondary 
hyperparathyroidism (SHPT) 
(A) The pyramid reflects a classical therapeutic strategy used in the past. Treatment 
usually started with dietary phosphate (P) restriction, P-binders [mainly calcium (Ca)-
based] and P removal by intensified dialysis therapy (increasing frequency or length of 
dialysis sessions). High-Ca dialysate baths were usually implemented. Increased 
parathyroid hormone (PTH) levels were initially treated by oral or intravenous calcitriol 
or alfacalcidol, and later selective vitamin D receptor activators (SVDRA, paricalcitol or 
maxacalcitol) and cinacalcet were added to the therapeutic armamentarium. Before 
the advent of new drugs, parathyroidectomy (PTX) was not uncommon. If available, 
renal transplantation (RT) is obviously the best option. 
(B) The description of the FGF -23/Klotho axis and the highest cardiovascular risk 
associated with vascular calcification (VC) helped to review paradigms on the 
pathophysiology and consequences of SHPT, to underline the importance of chronic 
kidney disease-mineral and bone disorders beyond bone, and to increase awareness on 
the potential importance of accelerated vascular calcification (VC) and atherosclerosis 
progression. A combination of drugs with less feed-back interactions may help to 
improve control not only of laboratory parameters (with lower doses and consequently 
adverse effects) but also to attenuate the progression of VC and/or potentially to 
improve hard-outcomes. Nicotinamide is an inhibitor of the intestinal Na-P2b 
cotransporter (there are others in different phases of development). Native vitamin D 
refers to native vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol), although 25-
(OH)-vitamin D (calcidiol or calcifediol) is also used in some countries to increase serum 
calcidiol levels. FGF-23: Fibroblast growth factor 23.  
 
